RESUMEN
The prevalence of metabolic syndrome (MS) was determined in patients aged < or =45 years who presented with acute myocardial infarction and underwent primary percutaneous coronary intervention. Two hundred twenty-three consecutive patients aged 18 to 45 years who underwent cardiac catheterization for acute myocardial infarction from June 2001 to December 2004 were reviewed. MS was diagnosed by National Cholesterol Education Program Adult Treatment Panel III guidelines (modified by substituting body mass index > or =28.8 kg/m2 for waist circumference). One hundred sixty-one patients met all 5 criteria for MS available for evaluation. Seventy-six of these patients (47%) met > or =3 of the 5 criteria for MS. Sixteen patients with MS (21%) and 5 patients without MS (6%) had diabetes mellitus. The prevalence of each criterion was significantly higher (p <0.05) in the MS group. Average Framingham risk scores were 7.0 and 4.5 for patients with and without MS, respectively. The prevalence of smoking, male gender, and family history of premature coronary artery disease were the same for the 2 groups. In conclusion, MS was highly prevalent in this population of young patients with acute myocardial infarction.
Asunto(s)
Angioplastia Coronaria con Balón , Síndrome Metabólico/epidemiología , Infarto del Miocardio/terapia , Adolescente , Adulto , Factores de Edad , Femenino , Humanos , Masculino , Síndrome Metabólico/complicaciones , Persona de Mediana Edad , Infarto del Miocardio/etiología , Prevalencia , Factores Sexuales , Fumar/efectos adversos , Estados Unidos/epidemiologíaAsunto(s)
Cardiopatía Carcinoide/patología , Neoplasias Cardíacas/patología , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Cardiopatía Carcinoide/tratamiento farmacológico , Neoplasias Cardíacas/tratamiento farmacológico , Tabiques Cardíacos/patología , Ventrículos Cardíacos/patología , Humanos , Neoplasias Intestinales/patología , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/secundario , Masculino , Persona de Mediana EdadRESUMEN
BACKGROUND: Chronic stress is estimated to increase the risk of cardiovascular (CV) events two-fold. Although stress reduction has been linked to a reduction in CV events, little is known regarding its exact mechanism of benefit. HYPOTHESIS: Yoga and meditation will improve parameters of endothelial function. METHODS: We examined the effects of yoga and meditation on hemodynamic and laboratory parameters as well as on endothelial function in a 6-week pilot study. Systolic and diastolic blood pressures, heart rate, body mass index (BMI), fasting glucose, lipids, hs C-reactive protein (CRP), and endothelial function (as assessed by brachial artery reactivity) were all studied at baseline and after 6 weeks of yoga practice. RESULTS: A course in yoga and meditation was given to the subjects for 1.5 h three times weekly for 6 weeks and subjects were instructed to continue their efforts at home. This prospective cohort study included 33 subjects (mean age 55 +/- 11 years) both with (30%) and without (70%) established coronary artery disease (CAD). There were significant reductions in blood pressure, heart rate, and BMI in the total cohort with yoga. None of the laboratory parameters changed significantly with yoga. For the total cohort there was no significant improvement in endothelial-dependent vasodilatation with yoga training and meditation compared with baseline (16.7% relative improvement from 7.2-8.4%; p = 0.3). In the group with CAD, endothelial-dependent vasodilatation improved 69% with yoga training (6.38-10.78%; p = 0.09). CONCLUSION: Yoga and meditation appear to improve endothelial function in subjects with CAD.
Asunto(s)
Arteria Braquial/fisiopatología , Meditación , Estrés Psicológico/fisiopatología , Estrés Psicológico/terapia , Yoga , Adulto , Anciano , Biomarcadores/sangre , Glucemia/metabolismo , Presión Sanguínea , Índice de Masa Corporal , Proteína C-Reactiva/metabolismo , Estudios de Casos y Controles , Enfermedad de la Arteria Coronaria/etiología , Enfermedad de la Arteria Coronaria/fisiopatología , Enfermedad de la Arteria Coronaria/terapia , Endotelio Vascular/fisiopatología , Femenino , Frecuencia Cardíaca , Humanos , Lípidos/sangre , Masculino , Persona de Mediana Edad , Análisis Multivariante , Proyectos Piloto , Estudios Prospectivos , Estrés Psicológico/complicaciones , Resultado del Tratamiento , VasodilataciónAsunto(s)
Dolor en el Pecho/etiología , Electrocardiografía , Infarto del Miocardio/diagnóstico , Vólvulo Gástrico/complicaciones , Vólvulo Gástrico/diagnóstico , Dolor Abdominal/etiología , Anciano de 80 o más Años , Cateterismo Cardíaco , Diagnóstico Diferencial , Femenino , Humanos , Vólvulo Gástrico/sangre , Tomografía Computarizada por Rayos X , Troponina/sangreRESUMEN
Recently, ephedra was removed from the U.S. marketplace due to a heightened concern that dietary supplements containing ephedra may present "an unreasonable risk of illness or injury." This is the 1st time the U.S. Food and Drug Administration has banned an herbal supplement, and the ban sheds light on the potential harm of nutritional supplements that are used for weight loss or as a boost to athletic performance. We report the case of a body builder who used Xenadrine RFA, an ephedra-containing supplement, at recommended doses for nearly a year; he then experienced an acute myocardial infarction, which was documented to be secondary to thrombosis in situ. We ruled out other possible causes of myocardial infarction, as well a hypercoagulable state. There was no evidence of illicit drug use. Our report serves as a poignant reminder of the potential dangers of herbal supplementation, especially when used to heighten athletic performance.